MRD-guided Treatment With Pembrolizumab and Azacitidine in NPM1mut AML Patients With an Imminent Hematological Relapse
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Azacitidine (Primary) ; Pembrolizumab (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms PEMAZA
- 29 Oct 2019 Status changed from not yet recruiting to recruiting.
- 16 Jul 2019 Planned End Date changed from 1 Dec 2021 to 1 Aug 2022.
- 16 Jul 2019 Planned primary completion date changed from 1 Dec 2020 to 1 Aug 2021.